The Patent System During Global Pandemic and the Access to Medications and Vaccines
Abstract
The Declaration on Trade-Related Intellectual Property Rights (TRIPS) and Public Health Agreements want to promote the balanced interpretation and implementation of its provisions and promote universal access by assisting WTO members to protect public health rights. Two years will soon pass, and the emergence of new variants of COVID-19 shows that the virus will not stop at national borders. However, vaccines are gradually entering and almost monopolised by industrialised countries. If Jonas Salk thought in the 1950s that patenting his polio vaccine was like patenting the sun, the problem appearing is that today's patent holders do not think so. The COVID-19 vaccine is owned by biotech companies, universities, research institutes or pharmaceutical companies. The purpose of this research is to analyse, through a normative juridical approach, the requirement for patent holders to protect their intellectual property rights if they are to remain competitive in the marketplace. Not to forget that they must pay patent fees as a percentage of the final price of the vaccine, which is a significant benefit to the economies of the countries where they are located. While for developing countries, the best solution would be to produce their vaccines. With industrial property rights, it seems impossible to transfer the vaccine technology on COVID-19. That is why some developing countries (South Africa and India have the support of many other developing countries) have filed a complaint with the WTO, requesting a waiver of property rights under Article 31 of TRIPS in order to produce a COVID-19 vaccine on a large scale and at an affordable price.
Keywords
Full Text:
PDFReferences
Anderson, Brin. "Better access to medicines: Why Countries are Getting “tripped” up and not ratifying article 31 bis", Case Western Reserve Journal of Law, Technology & the Internet (2010).
Attaran, Paul Champ and Amir. “Patent Rights and Local Working Under the WTO Trips Agreement: An Analysis of the U.S.-Brazil Patent Dispute.” Yale Journal of International Law 27 (2002).
Balaji, Aishu. “COVAX Protects the Vaccine Apartheid Status Quo,” n.d. https://www.jacobinmag.com/2021/05/covid-covax-vaccine-apartheid-wto-trips-intellectual-property-ip .
BBC. “Covid: US Backs Waiver on Vaccine Patents to Boost Supply,” n.d. https://www.astroawani.com/berita-malaysia/using-compulsory-licence-affordable-medicines-200558.
Canada - Patent Protection for Pharmaceutical Products (Complaint by the European Communities and their Member States), (2000) WTO Doc.WT/ DS114/R Panel Report para 4.21 page37.
Cassier, Maurice. “Industrial Property and Public Health. Project Magazine, Centre for Social Research and Action ; in French, Pro-Priété Industrielle et Santé Publique. Revue Projet, Centre de Recherche et d’action Sociales (C.E.R.A.S )” 270, no. 2 (2002). https://halshs.archives-ouvertes.fr/halshs-01893992/document.
“Communication of the EC Member States to the TRIPS Council Relating to Paragraph 6 of the Doha Declaration on the TRIPS Agreement and Public Health, Bruxelles, 18 Juin 2002,” n.d.
Doha WTO Ministerial. “TRIPS WT/MIN(01)/DEC/2 20 November 2001.Declaration on the TRIPS Agreement and Public Health Adopted on 14 November 2001,” 2001. https://www.wto.org/english/thewto_e/minist_e/min01_e/mindecl_trips_e.htm.
England’s Statute of Monopolies of 1623 (21 Jac. 1, c.3), while generally condemning monopolies, provided the true and first inventor of a given item up to fourteen years of exclusive rights to their invention, provided that: ...“they be not contrary to t (n.d.). https://en.wikisource.org/wiki/Statute_of_Monopolies .
Etat, Gabriel Galvez-behar L, and Gabriel Galvez-behar. “L’Etat et l’invention. Une Comparaison Franco-Allemande Des Cadres de La Propriété Industrielle à La Fin Du XIXè Siècle.,” 2010, 34. https://halshs.archives-ouvertes.fr/halshs-00010217/document .
Gervais, D. The TRIPS Agreement: Drafting History and Analysis, Londres, Sweet & Maxwell (1998).
Henderson, Gordon F. Patent Law of Canada, (Toronto, Carswell, 1997) (1997).
Hindle, Richard L. “Inventing Venice : An Urban and Environmental Innovation Model from the Lagoon City.” UC Berkeley, 2019, 531. https://escholarship.org/uc/item/75635711.
Hoen, Ellen ’t. “Covid-19 and the Comeback of Compulsory Licensing.” Medecines Law & Policy, n.d. https://medicineslawandpolicy.org/2020/03/covid-19-and-the-come-back-of-compulsory-licensing/. .
Klod, Olia i. “Pour Tout Savoir Sur Venise, Le Carnaval Vénitien et Les Costumé-E,” 2011. https://oliaklodvenitiens.wordpress.com/2011/03/19/parte-veneziana/ .
Lapointe, Serge. “L’histoire Des Brevets,” 2000. https://www.lescpi.ca/s/1972. .
Ling, Chee Yoke. “Using Compulsory Licence for Affordable Medicines,” n.d. https://www.astroawani.com/berita-malaysia/using-compulsory-licence-affordable-medicines-200558 .
Mappian, Émilie Bouchet-Le. “Intellectual Property and Property Law in English, German and French Law. In French; Propriété Intellectuelle et Droit de Propriété En Droits Anglais, Allemand et Français.” Presses universitaires de Rennes. Presses universitaires de Rennes, 2013.
Marre, V. B. “Rapport d’information Déposé Par La Délégation de l’Assemblée Nationale Pour l’Union Européenne Sur Le Bilan de La Conférence Ministérielle de l’OMC de Doha, 31 Janv,” 2002.
Mfuka Claude, TRIPS and pharmaceutical patents. “The Difficult Access of Developing Countries to AIDS Drugs Page 194, in French Accords ADPIC et Brevets Pharma-Ceutiques : Le Difficile Accès Des Pays En Développement Aux Médicaments Antisida. In.” Revue d’économie Industrielle 99, no. 2 (2002): 191–214.
Nash, Duane. “South Africa’s Medicines and Related Substances Control Act of 1997.” Berkeley Technology Law Journal 15 (2000): 485.
O Mitnovetski, D Nicol. “Are Patents for Methods of Medical Treatment Contrary to the Ordre Public and Morality or ‘Generally Inconvenient’?” Journal of Medical Ethics 30, no. 5 (2004): 470. https://doi.org/10.1136/jme.2002.000786.
OECD. “Coronavirus (COVID-19)Vaccines for Developing Countries: An Equal Shot at Recovery,” n.d. https://read.oecd-ilibrary.org/view/?ref=1060_1060300-enj5o5xnwj&title=Coronavirus-COVID-19-vaccines-for-developing-countries-An-equal-shot-at-recovery&_ga=2.5971899.909716357.1623330898-1992882103.1604019787 .
Organisation, World Health (WHO). "Fifty-Second World Health Assembly." Fifty-Second World Health Assembly, Geneva, 17-25 May 1999: Verbatim Records of Plenary Meetings and List of Participants. 52, no. 8649 (1999): 26.
Parlement Canada. “COVID-19 Emergency Response,” n.d. https://www.parl.ca/LegisInfo/BillDetails.aspx?Language=E&billId= 10710867.
Provisions, Annex I Patents Title I General. African Intellectual Property Organization (OAPI) Bangui Agreement (n.d.).
Rathod, Sandeep K. “Compulsory Licences on Pharmaceutical Patents in India: A Short Article.” Journal of Generics Medecines 13 (2017): 108.
Remiche, Desterbecq H. et B. Les brevets pharmaceutiques dans les accords du GATT : l’enjeu ?, Revue internationale de droit économique, X (1) (1996).
———. pharmaceutical patents in the GATT agreements: what is at stake? page 18, in french Les brevets pharmaceu-tiques dans les accords du GATT : l’enjeu ?, Revue internationale de droit économique, X (1) (1996).
Salazar, S. "Panel Discussion on Intellectual Property and Human Rights, Organised by the World Intellectual Property Organization Intellectual Property Organization (WIPO) Geneva." Intellectual Property and the Right to Health, no. 762 (1999): 65–91, 71.
Scherer, F. The patent system and innovation in the pharmaceutical field, in french, Le système des brevets et l’innovation dans le domaine pharmaceutique, Revue Internationale de Droit Economique, n°1 (2000).
Secaira, Jimmy Candell Soto and Raysa Vargas. “Resolution to Require the National Government to Establish Compulsory Licenses and Other Measures to Guarantee Free and Affordable Access to Pharmaceutical Products and Medical Technologies in the Declaration of Sanitary Emergency Due to the Coronavirus P.” postgraduates and students of the Public Health System, n.d. https://www.keionline.org/ecuador-CL-coronavirus-resolution.
Sidley, Pat. “Drug Companies Sue South African Government over Generics.” BMJ 24, no. 332 (2001): 447. https://doi.org/doi: 10.1136/bmj.322.7284.447.
Staff, Reuters. “Vaccine Patent Waiver Could Impact Quality of Shots –Merkel,” n.d. https://www.reuters.com/article/eu-india-merkel-idUSS8N2D400S.
the authorisation is given for the internal market of the Member State that allowed the use; the scope and duration of the authorisation are limited; the compulsory license is not transferable; the patent holder must receive adequate remuneration, etc. "The Patent Holder Must Have Refused a Voluntary License," n.d.
Thomann, Dirk De Bièvre Lars. Forum Shopping in the Global Intellectual Property Rights Regime, Arbeitspapiere – Working Papers Nr. 132, Mannheimer Zentrum für Europäische Sozialforschung (2010).
TRIPS Agreement.
Tsai, George. Canada’s Access to Medicines Regime: Lessons for Compulsory Licensing Schemes under the WTO Doha Declaration, 49 VA. J. INT’L L. (2009).
Valparaíso. “Resolution for the Granting of Non-Voluntary Licenses Referred to in Article 51 No 2 of Industrial Property Law N◦ 19.030 to Facilitate Access and Availability of Medicines and Technologies for the Prevention, Treatment and Cure of Coronavirus Covid-19,” n.d. https://www.keionline.org/chilean-covid-resolution.
WHO. “COVID-19 Technology Access Pool,” n.d. https://www.who.int/initiatives/covid-19-technology-access-pool .
———. “Waive Covid Vaccine Patents to Put World on War Footing 7 March 2021,” n.d. https://www.who.int/news-room/commentaries/detail/waive-covid-vaccine-patents-to-put-world-on-war-footing.
WTO. “Implementation of Paragraph 6 of the Doha Declaration on the TRIPS Agreement and Public Health, 30 August 2003, WT/GC/M/82,” n.d. https://www.wto.org/english/tratop_e/trips_e/implem_para6_e.htm .
———. “Protocol Amending the TRIPS Agreement, WT/L/540,” n.d. https://www.wto.org/french/tratop_f/trips_f/implem_para6_f.htm .
———. “Statistical Review of World Trade 2020.” Figure 4.34 Top 20 exporters of chemicals and pharmaceuticals, 2016. https://www.wto.org/french/res_f/statis_f/wts2016_f/wts2016_f.pdf .
nd US Communication on Paragraph 6 of the Doha Declaration on the TRIPS Agreement and Public Health, 25 June 2002, Document IP/C/W/358.
DOI: http://dx.doi.org/10.28946/slrev.Vol6.Iss1.1233.pp55-69
Refbacks
- There are currently no refbacks.
Sriwijaya Law Review (SLRev) ISSN: 2541-5298 | e-ISSN: 2541-6464 is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
